{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:42:04Z","timestamp":1789760524173,"version":"4.0.1"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"iCo Therapeutics Inc."}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,9,21]]},"abstract":"<jats:p>This study evaluated the safety, tolerability, and pharmacokinetics of a novel oral amphotericin B (AmB) formulation (iCo-019) following single doses to healthy humans. The data from this study suggest that iCo-019 has a long circulation time and systemic exposure without the associated gastrointestinal, liver, and kidney toxicity associated with AmB. This novel oral AmB formulation can serve as a new treatment strategy to overcome the limitations of the use of parenterally administered AmB products.<\/jats:p>","DOI":"10.1128\/aac.01450-20","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:58:37Z","timestamp":1594904317000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration"],"prefix":"10.1128","volume":"64","author":[{"given":"Peter","family":"Hnik","sequence":"first","affiliation":[{"name":"iCo Therapeutics Inc., Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen K.","family":"Wasan","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor M.","family":"Wasan","sequence":"additional","affiliation":[{"name":"iCo Therapeutics Inc., Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200311130812"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11030099"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.03.013"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.08.042"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.02.008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp140"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000913"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/600105"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/08982104.2017.1380664"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2018.1515225"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2016.1228715"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.01.003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-3084(96)02652-7"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.05.013"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-015-0267-6"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2014.891271"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S95194"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.05.044"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2018.01.023"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-017-0452-x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/564573"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2013.04.053"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir735"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-012-9876-2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp500527x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982100009031116"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2704-2707.2002"},{"key":"e_1_3_2_30_2","unstructured":"Kalbag S Lu R Ngoje J Mannino RJ. 1992. Oral administration of amphotericin B: toxicokinetic studies in animal models. https:\/\/d1io3yog0oux5.cloudfront.net\/_5302c050e2e7c359ceb9446db98d9937\/matinasbiopharma\/db\/284\/2327\/pdf\/CAmB-Focus-Tox-Poster.pdf."},{"key":"e_1_3_2_31_2","unstructured":"Matinas Biopharma. 2018. MAT2203: LNC formulation of amphotericin B. https:\/\/www.matinasbiopharma.com\/pipeline\/mat2203-lnc-formulation-of-amphotericin-b. Accessed on 15 September 2018."},{"key":"e_1_3_2_32_2","unstructured":"Mannino R De B Teae A. 2019. Oral administration of amphotericin B (CAmB) in humans: a phase I study of tolerability and pharmacokinetics preliminary pharmacokinetics. https:\/\/content.equisolve.net\/_db6027646f523d19fe795801a0b7aff1\/matinasbiopharma\/db\/128\/510\/pdf\/Oral_Dosing_of_Encochleated_Amphotericin_B_%28CAmB%29__Rapid_Drug_Targeting_to_Infected_Tissues_in_Mice_with_Invasive_Candidiasis.pdf. Accessed on 21 February 2019."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-10-135"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01450-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01450-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:36:44Z","timestamp":1645486604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01450-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,21]]}},"alternative-id":["10.1128\/AAC.01450-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01450-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"2020-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01450-20"}}